Cathepsin B-Like Activity as a Serum Tumour Marker in Ovarian Carcinoma

Clinical Chemistry and Laboratory Medicine

Volumn 35, Issue 4, 1997, Pages 301-304

  Warwas, Maria ^a   Haczyńska, Haiina ^a   Gerbet, Jerzy ^a   Nowak, Marek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CYSTATIN; PAPAIN; TUMOR MARKER;

ARTICLE; BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; UTERUS MYOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATHEPSIN B; CYSTATINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEIOMYOMA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN CYSTS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 0030917299     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1997.35.4.301     Document Type: Article

References (25)

1. Mutch DG, Williams S. Biology of epithelial ovarian cancer. Clin Obstet Gynecol 1994: 37: 406-422.
2. Pearson VAH. Screening for ovarian cancer: a review. Public Health 1994: 108: 367-382.
3. Devine PL, McGuckin MA, Quin RJ, Ward BG. Predictive value of the combination of serum markers, CA 125, CAS A and TPS in ovarian cancer. Int J Gynecol Cancer 1995: 5: 170-178.
4. Medl M, Ogris E, Peters-Engl C, Leodolter S. TATI (tumourassociated trypsin inhibitor) as a marker of ovarian cancer. Br J Cancer 1995: 71: 1051-4.
5. Sliutz G, Tempfer C, Kainz Ch, Mustafa G, Gitsch G, Koelbi H, et al. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. AnticancerRes 1995: 15: 1127-30.
6. Nagele F, Petru E, Medl M, Kainz Ch, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995: 86: 259-264.
7. Pietras RJ, Szego CM, Mangan CE, Seeler BJ, Burtnett MM. Elevated serum cathepsin B l-like activity in women with neoplastic disease. Gynecol Oncol 1979: 7: 1-17.
8. Sloane BF, Moin K, Krepela E, Rozhin J. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev 1990: 9: 333-352.
9. Averette HE, Donato DM. Ovarian carcinoma. Advances in diagnosis, staging and treatment. Cancer 1990: 65: 703-708.
10. Szego CM, Seeler BJ, Smith RE. Lysosomal cathepsin Bl: partial characterization in rat preputial gland and recompartmentation in response to estradiol-17β. Eur J Biochem 1976: 69: 463-474.
11. Minakata K, Asano M, Sato T, Harada N. Asay of a-cysteine proteinase inhibitor in serum or plasma. Z Physiol Chem Hoppe-Seyler 1982: 363: 493-498.
12. Sasaki M, Minakata K, Yamamoto H, Niwa M, Kato T, Ito N. A new component which specifically inhibits thiol proteinases. Biochem Biophys Res Commun 1977: 76: 917-924.
13. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, et al. L-trans-Epoxysuccinyl-leucylamido (4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsin B, H and L. Biochem J 1982: 201: 189-198.
14. Schwartz MK. Tissue cathepsin as tumor markers. Clin Chim Acta 1995: 237: 67-78.
15. Gabrijelcic D, Annan-Prah A, Skrk J, Kramberger M, Sebek S, Turk V. Determination of cathepsin B and H in sera and tissues of breast cancer patients. Period Biol 1990: 92: 154-155.
16. Dufek V, Jirasek V, Krai V, Matous B, Drazna E. Changes in serum cathepsin B-like activity in patients with colorectal cancer. Neoplasma 1985: 32: 51-54.
17. Hirano T, Manabe T, Takenchi S, Immura M. Serum cathepsin B levels and tissue cathepsin B content in the patients with gastrointestinal malignancies. Med Sei Res 1993: 21: 343-344.
18. Krcicki T, Siewinski M. Serum cathepsin B-like activity as a potential marker of laryngeal carcinoma. Eur Arch Otorhinolaryngol 1992: 249: 293-295.
19. Dufek V, Matous B, Krai V. Serum alkaline-stable acid thiol proteinase-a possible marker for primary liver carcinoma. Neoplasma 1984: 31: 99-107.
20. Makarewicz R, Drewa G, Szymański W, Skonieczna-Makarewicz I. Cathepsin B in predicting the extent of the cervix carcinoma. Neoplasma 1995: 42: 21-24.
21. Benitez-Bribiesca L, De La Huerta-Sanchez R, Villaneueva C, Freyre-Horta R, Pastrana L, Guevara R. Proteinase and antiproteinase balance in patients with carcinoma of the uterine cervix before and after radiotherapy. Archiv Invest Med (Mexico) 1989: 20: 9-21.
22. Kozyreva EA, Zhordaniia KI, Bassalyk LS, Vasiliev AV. Proteolytic lysosomal enzymes in ovarian cancer. Vopr Med Khim 1991: 37: 20-30.
23. Calkins C, Sloane BF. Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. Biol Chem Hoppe-Seyler 1995: 376: 71-80.
24. Assfalg-Machleidt I, Jochum M, Klaubert W, Inthom D, Machleidt W. Enzymatically active cathepsin B dissociating from its inhibitor complexes is elevated in blood plasma of patients with septic shock and some malignant tumors. Biol Chem Hoppe-Seyler 1988: 369: 263-269.
25. Warwas M, Gerber J, Pietkiewicz A. Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary. Neoplasma 1986: 33: 79-84.